Welcome to our dedicated page for Hims & Hers Health news (Ticker: $HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hims & Hers Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hims & Hers Health's position in the market.
Hims & Hers Health, Inc. reported strong financial results for Q1 2024 with revenue of $278.2 million, up 46% YoY, net income of $11.1 million, and adjusted EBITDA of $32.3 million. Subscribers grew to 1.7 million, a 41% increase YoY. The company raised its full-year 2024 guidance to $1.20 billion to $1.23 billion in revenue and $120 million to $135 million in adjusted EBITDA.
